Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.70 |
| ▸ | IDO1 | P14902 | 9/20 | 0.60 |
| ▸ | TDO2 | P48775 | 4/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17070929 | 0.87 | GSK3B (0.58) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL7372759 | 0.87 | GSK3B (0.73) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL28649392 | 0.87 | GSK3B (0.73) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL18025747 | 0.87 | GSK3B (0.73) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL8806656 | 0.87 | GSK3B (0.72) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL38657178 | 0.86 | GSK3B (0.68) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL31613809 | 0.85 | GSK3B (0.56) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL5667881 | 0.85 | GSK3B (0.56) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL28648105 | 0.83 | GSK3B (0.68) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL18025766 | 0.83 | GSK3B (0.68) | GSK3BMAPTKDM4EGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109320447-B | Synthesis method of chiral 3, 3-disubstituted indole-2-ketone derivative | 上海工程技术大学 | 2021-10-08 | — | — | CN | disclosed |
| US-9701684-B2 | Chiral fluorinating reagents | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| WO-2016133217-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE OXINDOLE COMPOUND AND TRIAZOLIUM SALT USED THEREIN AS CATALYST | 国立大学法人名古屋大学 | 2016-08-25 | — | — | WO | disclosed |
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2015-10-08 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980926-B2 | 2-aminoindole compounds and methods for the treatment of malaria | GENZYME CORPORATION (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2014068341-A2 | CHIRAL FLUORINATING REAGENTS | ISIS INNOVATION LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2012-09-13 | — | — | US | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| CN-1157822-A | Pharmaceutical compounds | LILLY INDUSTRIES LTD (GB) | 1997-08-27 | — | — | CN | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
| US-RE29882-E | SALT FORMATION, REARRANGEMENT, DESULFURIZATION | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1979-01-16 | — | — | US | disclosed |
| US-4056569-A | Ortho-[(alkylthio)(aminocarbonyl)methyl]anilines | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1977-11-01 | — | — | US | disclosed |
| US-4053613-A | 1,3,THIAZOLINYL AND 1,3 THIAZINYL SUBSTITUTED INDOLINONES | E. R. SQUIBB & SONS, INC. (US) | 1977-10-11 | — | — | US | disclosed |
| US-3996264-A | Synthesis of oxindoles from anilines and intermediates therein | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3972894-A | Synthesis of oxindoles from anilines and β-thio carboxylic esters or amides | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1976-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284401-A1 | CHIRAL FLUORINATING REAGENTS | TIAM1, AFF2, AFF1 | GSK3B 1199/4885MAPT 3516/4885KDM4E 3807/4885 |
| US-20120232063-A1 | 2-Aminoindole Compounds And Methods For The Treatment Of Malaria | PNMT, AADAT, INMT | GSK3B 2302/4885MAPT 621/4885KDM4E 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.